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Background: Artemisinin-based fixed dose combination (FDC) products are recommended by World Health
Organization (WHO) as a first-line treatment. However, the current artemisinin FDC products, such as β-artemether
and lumefantrine, are inherently unstable and require controlled distribution and storage conditions, which are not
always available in resource-limited settings. Moreover, quality control is hampered by lack of suitable analytical
methods. Thus, there is a need for a rapid and simple, but stability-indicating method for the simultaneous assay of
β-artemether and lumefantrine FDC products.
Methods: Three reversed-phase fused-core HPLC columns (Halo RP-Amide, Halo C18 and Halo Phenyl-hexyl), all
thermostated at 30°C, were evaluated. β-artemether and lumefantrine (unstressed and stressed), and reference-related
impurities were injected and chromatographic parameters were assessed. Optimal chromatographic parameters were
obtained using Halo RP-Amide column and an isocratic mobile phase composed of acetonitrile and 1mM phosphate
buffer pH 3.0 (52:48; V/V) at a flow of 1.0 ml/min and 3 μl injection volume. Quantification was performed at 210 nm and
335 nm for β-artemether and for lumefantrine, respectively. In-silico toxicological evaluation of the related impurities was
made using Derek Nexus v2.0W.
Results: Both β-artemether and lumefantrine were separated from each other as well as from the specified and
unspecified related impurities including degradants. A complete chromatographic run only took four minutes. Evaluation
of the method, including a Plackett-Burman robustness verification within analytical QbD-principles, and real-life samples
showed the method is suitable for quantitative assay purposes of both active pharmaceutical ingredients, with a mean
recovery relative standard deviation (± RSD) of 99.7 % (± 0.7%) for β-artemether and 99.7 % (± 0.6%) for lumefantrine. All
identified β-artemether-related impurities were predicted in Derek Nexus v2.0W to have toxicity risks similar to
β-artemether active pharmaceutical ingredient (API) itself.
Conclusions: A rapid, robust, precise and accurate stability-indicating, quantitative fused-core isocratic HPLC method
was developed for simultaneous assay of β-artemether and lumefantrine. This method can be applied in the routine
regulatory quality control of FDC products. The in-silico toxicological investigation using Derek NexusW indicated that the
overall toxicity risk for β-artemether-related impurities is comparable to that of β-artemether API.
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Malaria is endemic throughout most of the tropics where
approximately three billion people, living in 108 coun-
tries, are exposed. Approximately 243 million people an-
nually develop symptomatic malaria [1]. Most of these
can be attributed to Plasmodium falciparum, but Plas-
modium vivax and Plasmodium knowlesi can also cause
severe diseases. An estimated 3.3 billion people were at
risk of malaria in 2010 with populations living in sub-
Saharan Africa having the highest risk of acquiring mal-
aria, and children under five years of age and pregnant
women being most severely affected [2,3]. Malaria case
management remains a vital component of malaria con-
trol strategies. This entails early diagnosis and prompt
treatment with effective anti-malarial medicines [4]. The
World Health Organization (WHO) has recommended
that all anti-malarials should consist of a combination
of an artemisinin derivative with a co-drug such as
lumefantrine, amodiaquine or mefloquine; most malaria
endemic countries have now adopted artemisinin-based
anti-malarial combination therapy (ACT) as first-line
treatment of P. falciparum malaria in place of chloro-
quine, quinine and sulphadoxine-pyrimethamine fixed
dose combinations [5]. However, the emergence of re-
sistance is of great concern [6-8], and this problem is
fuelled by poor quality anti-malarial drugs.
Poor quality anti-malarials are a severe under-
recognized public health problem, reducing the effective-
ness of these drugs and threatening current treatment
policies [9]. There are three main types of poor quality
medicines: substandard, degraded and counterfeit. Sub-
standard drugs are produced with inadequate attention
to good manufacturing practices and may have content
outside accepted limits. Degraded formulations may re-
sult from (unwanted) exposure of initially well produced,
good quality medicines to light, heat and humidity
[10,11]. Therefore, the ultimate purpose of stability testing
is to provide evidence on how the quality of a drug varies
with time under the influence of a variety of environmentalFigure 1 Structure of β-artemether (Art) and lumefantrine (Lum).factors such as temperature, humidity and light and en-
ables recommendations of storage conditions, retest pe-
riods and shelf life to be established. The two main
chemical aspects of the drug product that play an import-
ant role in shelf-life determinations are the assay of active
drug (efficacy) and degradants generated during the stabil-
ity study (safety). The assay of drug product in stability test
samples obviously needs to be determined using a stability-
indicating method, as recommended by the International
Conference on Harmonization (ICH) guidelines [12,13].
Moreover, the intrinsic stability of a finished drug product
should also be considered as a possible quality attribute
when evaluating and comparing different drug products
with the same active pharmaceutical ingredient (API). For
example, it has been demonstrated that the half-life of
β-artemether-containing products at 50°C can range be-
tween 0.70 and 9.52 months [14].
β-artemether is a methyl ether derivative of artemi-
sinin, which is a peroxide lactone isolated from the
Chinese anti-malarial plant Artemisia annua (Figure 1).
Chemically, it is (+)-(3-alpha,5a-beta,6-beta,8a-beta,9-
alpha,12-beta,12aR)-decahydro-10-methoxy-3,6,9-trimethyl-
3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin [15].
Lumefantrine (benflumetol) is a 2,4,7,9-substituted fluorene
(2,3-benzindene) derivative (Figure 1). Chemically, it
is (9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylene]-a-
[dibutylamino) methyl]-9H-fluorene-4-methanol [16].
Both compounds are now commercially available in fixed
combination products (ACT), which are proven to be
highly efficacious for treatment of uncomplicated P. falcip-
arum malaria. The increasing use of these β-artemether-
lumefantrine combination anti-malarial products and the
intrinsic stability of these products requires controlled stor-
age conditions. However, in resource-limited settings, sta-
bility of these products is not guaranteed since the supply
chains do not have consistently appropriate temperature
and humidity quality assurance systems [17]. Therefore, it
is important to have a rapid, but robust and stability-
indicating quantitative method for the simultaneous assay
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ation (FDC) products.
Currently, there are HPLC methods for the assay of
β-artemether in finished pharmaceutical products (FPP)
[18-20], as well as for lumefantrine analysis [21-23]. Only a
few HPLC methods were reported for the quantitative de-
termination of β-artemether and lumefantrine in fixed
combination anti-malarial products [24-26]. However, no
simple, rapid and proven stability-indicating method has
been reported for the simultaneous analysis of both active
pharmaceutical drug products. Hence, the present study
reports a rapid, economical, precise and accurate method
for the assay of β-artemether and lumefantrine in the pres-
ence of their degradants.
Methods
Samples and chemicals
β-artemether and lumefantrine APIs, Co-ArtesianeW FPP
powder for oral suspension, dihydroartemisinin (DHA),
artemisinin, 9,10-anhydroartemisinin (AHA; late eluting
impurity (LEI)) and α-artemether standards were supplied
by Dafra Pharma International (Belgium). CoartemW
and ArtemineW samples were collected from different
markets in Ethiopia. Analytical solutions were pre-
pared using HPLC grade unstabilized tetrahydrofuran
(THF) (Fisher Scientific, Leicestershire, UK) obtaining
a concentration of 0.2 mg/ml β-artemether and 1.2 mg/ml
lumefantrine corresponding to 100% label claim (lc).
Hydrogen peroxide (H2O2) and sodium hydroxide (NaOH)
were purchased from Merck (Darmstadt, Germany),
hydrochloric acid (HCl) and o-phosphoric acid from
Sigma-Aldrich (St Louis, USA). Sartorius (Göttingen,
Germany) ultrapure 18.2 mΩ.cm quality water and
HPLC grade acetonitrile (Fisher Scientific, UK) were
used for HPLC-UV analysis.
Liquid chromatography and analytical conditions
The HPLC analyses were carried out using HPLC-PDA
apparatus consisting of a Waters Alliance 2695 separ-
ation module and a Waters 2998 photodiode array de-
tector with Empower 2 software for data acquisition
(all Waters, Milford, MA, USA). The following fused-core
stationary-phase chemistries were evaluated: (i) Halo RP-
Amide (50×4.6 mm id; 2.7 μm particle size); (ii) Halo C18
(50×4.6 mm id; 2.7 μm particle size); and, (iii) Halo
Phenyl-hexyl (50×4.6 mm id; 2.7 μm particle size), all
Achrom (Machelen, Belgium) and all thermostated at
30°C. Detection was performed from 190–400 nm.
Lumefantrine quantification was done at 335 nm, a wave-
length at which β-artemether and its related impurities are
not absorbing. For β-artemether, quantification was
performed at 210 nm. As N-oxide-lumefantrine might
interfere if present, back-calculating the peak area of N-
oxide-lumefantrine using peak area conversion factor from335 nm to 210 nm (1.64) was performed and the obtained
value was subtracted from the peak area at 210 nm. The
injection volume was 3 μl. Isocratic mobile phases
containing acetonitrile and 1 mM phosphate buffer pH 3.0
were used at a flow of 1.0 ml/min. The separation of
β-artemether and lumefantrine was evaluated using dif-
ferent proportions of these mobile phase solvents and,
for each condition, the retention factor (k’) and asym-
metry factor (As) were calculated based on the method
described in European Pharmacopoeia (Ph. Eur.) 2.2.46
[27] (see Additional file 1). The optimal condition was
achieved using the Halo RP-Amide column and a mo-
bile phase composed of acetonitrile and 1 mM phos-
phate buffer pH 3.0 (52:48 V/V).
Preparation of solutions
Preparation of β-artemether and lumefantrine standard
solution
Approximately 20.0 mg β-artemether and 120.0 mg
lumefantrine reference standards were accurately weighed
and transferred to a 100.0 ml volumetric flask. Eighty ml
tetrahydrofuran was added to dissolve both com-
pounds and the solution was diluted to volume using
mobile phase.
Preparation of test sample solutions
Four samples of fixed dose combination tablets (CoartemW
and ArtemineW) containing 20 mg β-artemether and
120 mg lumefantrine and three powders for oral sus-
pension stability samples (Co-artesianeW) containing
180 mg β-artemether and 1080 mg lumefantrine were
analysed using the validated fused-core HPLC method.
For this, a homogenous FPP powder amount equivalent
to 20.0 mg β-artemether and 120.0 mg lumefantrine
was accurately weighed and transferred to a 100.0 ml
volumetric flask. Eighty ml tetrahydrofuran was added,
shaken for 5 min and diluted to volume using mobile
phase. The mixture was filtered through 0.45 μm HPLC
syringe filters and analysed using HPLC.
Preparation of stress solutions
Preparation of oxidative degradation of lumefantrine API
solution
Approximately 120.0 mg lumefantrine API was accur-
ately weighed and transferred into 100 ml Erlenmeyer
flask; 45.0 ml tetrahydrofuran was added to ensure
complete dissolution of lumefantrine and then 5.0 ml
30% hydrogen peroxide was added. The solution was
boiled for 120 min under constant reflux and analysed
using HPLC.
Preparation of acidic degradation of lumefantrine solution
Approximately 120.0 mg of lumefantrine API was accur-
ately weighed into 100 ml Erlenmeyer flask; 10.0 ml of 1 M
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70°C for 30 hours. Subsequently, the solution was neutral-
ized by addition of 2.0 ml of 5 M sodium hydroxide solu-
tion and then 38.0 ml of THF was added. The mixture was
sonicated for 5 min, filtered and analysed.
Preparation of heat stressed β-artemether API solution
Preparation of heat stressed β-artemether was performed
as described by De Spiegeleer et al. [20]. Briefly, approxi-
mately 20.0 mg of β-artemether API was accurately
weighed and transferred into a glass HPLC vial. The vial
was put in a heating block at 145°C for 30 min, resulting
in approximately 70% conversion of β-artemether to re-
lated degradation products. Then 1.0 ml tetrahydrofuran
was added and the solution was quantitatively trans-
ferred to a 50.0 ml volumetric flask by addition of 40 ml
tetrahydrofuran. The solution was then diluted to vol-
ume using mobile phase.
Validation
Linearity
A stock solution containing 250 μg/ml β-artemether and
1,500 μg/ml lumefantrine in THF was prepared in tripli-
cate. Different aliquots of these solutions were diluted in
a dilution solvent consisting of THF/mobile phase (80:20
V/V) to five different concentrations, corresponding to
160, 180, 200, 220 and 240 μg/ml of β-artemether, and
960, 1,080, 1,200, 1,320 and 1,440 μg/ml of lumefantrine.
Calibration curves for concentration versus peak area
were plotted for each compound and the obtained data
were subjected to linear regression analysis.
Precision
For intra-day precision, six sample solutions (n=6) were
prepared at 0.2 mg/ml β-artemether and 1.2 mg/ml
lumefantrine concentrations and analysed using HPLC.
Similarly, the inter-day precision was evaluated in three
consecutive days (n=3×6). β-artemether and lumefantrine
concentrations were determined and relative standard de-
viations (RSD) were calculated.
Accuracy (recovery test)
Accuracy was tested by recovery experiments where
β-artemether and lumefantrine reference solutions
were added to a placebo sample at three levels: 75%,
100% and 125% of the label claim. At each level,
samples were prepared in duplicate and recovery per-
centage was calculated.
Selectivity
Selectivity of the method was evaluated by injecting the
stressed β-artemether and lumefantrine solutions as well
as reference standard solutions of α-artemether, artemi-
sinin, DHA and AHA. Moreover, UV-spectral purities ofβ-artemether and lumefantrine chromatographic peaks
were evaluated using Waters’ peak purity PDA evaluation.
Robustness
A Plackett-Burman experimental design consisting of
12 experiments with two replicates in block was used
for the robustness testing (Modde version 8, Umetrics
Inc, USA). Three sample solutions (stressed, test sam-
ple and reference solutions) were prepared at 100% lc
and analysed using different experimental conditions
by varying different analytical parameters: flow (0.8,
1.0, and 1.2 ml/min), acetonitrile proportion (50%, 52%
and 54%), mobile phase pH (2.8, 3.0 and 3.2), and column
temperature (25°C, 30°C and 35°C). β-artemether and
lumefantrine contents and different chromatographic char-
acteristics were determined under each condition.
Limit of detection (LoD) and limit of quantitation (LoQ)
Combined standard solutions of β-artemether and
lumefantrine were prepared by serial dilutions, ranging
from 0.4 to 25 μg/ml for β-artemether and 0.2 to
11.5 μg/ml for lumefantrine, and injected onto the
chromatographic system. The LoD was defined as the
concentration for which a signal-to-noise ratio (S/N) of
three was obtained and LoQ was considered to be the
concentration at which S/N was 10.
In-silico toxicological predictions
In-silico toxicological study for lumefantrine and its re-
lated impurities was reported in previous publication
[23]. Exhaustive impurity profiling of β-artemether
(including its possible degradants) was also reported
[20,28]. Therefore, to make in-silico toxicological com-
parative predictions for β-artemether and its identified
related impurities, Derek Nexus v2.0 for Windows de-
veloped by Lhasa Ltd (Leeds, UK) was used. Derek
NexusW is an expert knowledge-based system, containing
descriptions of molecular substructures which have been
associated with toxic endpoints (structural alerts), that
predicts a probability whether a chemical is toxic in
humans, other mammals and bacteria. The program ap-
plies structure-activity relationships [(Q)SARs] and expert
knowledge rules to derive a reasoned conclusion about
the potential toxicity of the query chemical [29-31].
Results
Development
To develop a rapid, simple and stability-indicating iso-
cratic HPLC method, three different fused-core station-
ary phases (Halo phenyl-hexyl, Halo C18 and Halo
RP-Amide) and a mobile phase with different composi-
tions of acetonitrile and 1 mM phosphate buffer with
varying pH (3.0, 5.0 and 7.0) were used. Relatively longer
run time was obtained with 1 mM phosphate buffer
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lumefantrine. At all conditions, there was no separation
between β-artemether and lumefantrine using Halo
phenyl-hexyl stationary phase. Using Halo C18 stationary
phase column and a mobile phase composed of aceto-
nitrile and 1 mM phosphate buffer pH 3.0, the retention
factors obtained for β-artemether and lumefantrine were
11.8 and 3.0, respectively. Under these conditions, in
spite of achieving good separation between β-artemether
and lumefantrine, the peak shape of lumefantrine
was found to be out of pharmacopoeial specifications
(Ph Eur. specification As ≤ 1.5) [27] and the total
run time was relatively long, i e, 6 min. Substituting
the Halo C18 with a Halo RP-Amide stationary phase,
different proportions of mobile phase solvents were
evaluated (Table 1). The optimal mobile phase, com-
posed of acetonitrile and 1 mM phosphate buffer pH
3.0 (52:48, V/V), gave an adequate retention factor k’
and lumefantrine peak shape (As 1.3) that complies
with pharmacopoeial specifications within a short
period of total run time of 4 min (Figure 2).
As indicated in the UV-spectra of Figure 2, β-artemether
only shows reasonable UV-absorption at the lower wave-
lengths of the spectrum (200-230 nm), due to the absence
of UV-chromophores in its structure. Thus, its quantifica-
tion was performed at 210 nm. For lumefantrine with a RT
of 1.70 min, quantification was performed at 335 nm, the
wavelength at which no UV-absorption interference from
β-artemether was observed.
It was reported that the desbenzyl keto derivative
(DBK) is the major degradation product after acidic
degradation of lumefantrine, while the oxidative deg-
radation of lumefantrine was reported to yield N-
oxide-lumefantrine [23]. Under the chromatographic
conditions, DBK eluted before lumefantrine at reten-
tion time (RT) of 1.26 min, while N-oxide-lumefantrine
was eluting after lumefantrine at RT of 3.17 min (see
Additional file 1).
As indicated in Table 2, β-artemether and all its iden-
tified related impurities (α-artemether, DHA, artemisi-
nin and AHA) were eluting at different RT without any
interference with the main peak. Previous studies have
indicated that AHA-β-artemether is the most critical
pair to be separated [28], while other impurities likeTable 1 Chromatographic parameters for β-artemether and lu
Halo RP-Amide stationary phase column
Mobile phase composition; Acetonitrile:
1mM phosphate buffer pH 3.0
β-artemether
retention factor (k’)
β-
sy
54:46 5.5 1.0
52:48 6.8 1.0
50:50 7.5 1.0
to = 0.4 min.DKA or furano acetate are sufficiently well separated
from β-artemether. Moreover, lumefantrine and its re-
lated degradation impurities (DBK and the N-oxide of
lumefantrine) were also eluting at different RT. How-
ever, while some of β-artemether impurities (DHA, ar-
temisinin and other degradation products from dry heat
stress β-artemether) co-elute with lumefantrine, which
however does not interfere with its assay due to negli-
gible UV-absorption of these β-artemether impurities at
335 nm, the N-oxide-lumefantrine problematically co-
elutes with β-artemether peak, making selective quantifica-
tion of β-artemether at 210 nm difficult. Therefore, the
method quantifies lumefantrine separated from its related
impurities at 335 nm (where β-artemether and its related
impurities are not absorbing). Since lumefantrine and its
related impurities have strong UV absorption at 210 nm
and N-oxide-lumefantrine is co-eluting with β-artemether,
it is possible to selectively obtain the UV210 nm peak area of
β-artemether alone by back-calculating the peak area of
N-oxide-lumefantrine using the peak area conversion fac-
tor from 335 nm to 210 nm (i.e, 1.64) and subtracting the
value from the co-eluting peak area at 210 nm.
Therefore, compared to the method described in Ph. Int.
[26], which uses conventional HPLC, the developed fused-
core method uses simple sample extraction technique and
is isocratic, rapid, less costly and stability-indicating.
Validation
Linearity
Almost all the variation in peak area was explained by
the linear concentration (0.9997 for β-artemether and
0.9997 for lumefantrine), indicating the linearity of the
method in the assayed range (80 to 120% label claim).
The regression analysis data are presented in Table 3.
Precision
In the prepared solutions for analysis, 100% label claim
(lc) represents 0.2 mg/ml β-artemether and 1.2 mg/ml
lumefantrine solution.
Intra-day precision
Mean contents and RSD of β-artemether and lumefantrine
in the intra-day precision analysis (n=6) were 99.6% lc with
RSD = 1.2% and 99.2% lc with RSD = 0.5%, respectively.mefantrine at different mobile phase compositions using
artemether peak
mmetry factor (As)
Lumefantrine
retention factor (k’)
Lumefantrine peak
symmetry factor (As)
1.5 1.4
2.0 1.3
2.8 1.8
Figure 2 Typical chromatogram obtained on solution of β-artemether (Art) (RT: 3.07min) and lumefantrine (Lum) (RT: 1.70 min) in
tetrahydrofuran (THF) with their UV spectrum in the infronts.
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Mean contents and RSD values of β-artemether and
lumefantrine in the inter-day precision analysis (n=3×6)
were 99.6% lc with RSD = 1.1% and 99.4% lc with RSD =
0.6%), respectively.
For both compounds, the intra-day and inter-day pre-
cision % RSD values were lower than 2.0%, revealing
precision of the method [32].
Accuracy (recovery test)
The recovery test was performed by analysing a spiked
placebo. β-artemether mean recovery (n=6) was 99.7%
(RSD = 0.7%) and lumefantrine mean recovery was 99.7%
(RSD = 0.6%), indicating the accuracy of the method.
Selectivity
The chromatograms obtained with the stressed lume-
fantrine API solutions showed degradation impurity
peaks separated from the main API peak, and similar
findings were observed for the stressed β-artemether
solutions. Acid-stressed lumefantrine resulted in DBK
eluting before lumefantrine at RT of 1.26 min, while
oxidative stress resulted in N-oxide-lumefantrine elut-
ing after lumefantrine at RT of 3.17 min. β-artemether
and all its identified related impurities (α-artemether,Table 2 Retention time (RT) for β-artemether and lumefantrin
# β-artemether DHA Artemisinin α-artemether
RT (min) 3.07 1.62 1.68 2.14DHA, artemisinin and AHA) were eluting at different
RT without any interference with the β-artemether
peak. However, at 210 nm, N-oxide-lumefantrine was
co-eluting with β-artemether and some degradants of
β-artemether were co-eluting with lumefantrine. There is
no interference from β-artemether and its impurities for
the estimation of lumefantrine and its related impurities
at 335 nm. Therefore, for the quantification of the two
APIs, the method uses two wavelengths, 210 nm for
β-artemether and 335 nm for lumefantrine.
The peak purity indices for both β-artemether and
lumefantrine in different marketed FDC anti-malarial drug
sample solutions determined with PDA detector under op-
timized chromatographic conditions indicated that the
purity angle for both APIs was less than the purity thresh-
old, revealing no significant excipient interference.
Robustness
A Plackett-Burman design was used to test the robust-
ness of the method. Plackett-Burman design is a two
level fractional factorial design where main effects are
heavily confounded with two factor interactions. It is se-
lected for robustness evaluation since it combines less
experimentation with maximal information acquisition
in the most efficient way.e and their related impurities
AHA Lumefantrine DBK N-oxide of lumefantrine
2.71 1.70 1.26 3.17
Table 3 Calibration curve for β-artemether and
lumefantrine
Regression parameters β-artemether Lumefantrine
Regression coefficient, R2 0.9997 0.9997
Slope ± standard error 103.1±1.1 4880.8±51.8
Intercept ± standard error 1708.1±235.7 224820.8±62658.3
Relative standard error (%) 1.1 1.1
Concentration range (μg/ml) 160-240 960-1440
F-value 8060.4 8876.5
Number of points 5 5
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method settings, were considered: percentage V/V of
acetonitrile in mobile phase (from 50 to 54%), flow (from
0.8 to 1.2 ml/min), pH (from 2.8 to 3.2) and column
temperature (from 25 to 35°C) (see Additional file 1).
Mobile phase pH significantly affects the peak shape of
lumefantrine while it did not reveal prominent influence
on that of β-artemether. Thus, lumefantrine peak sym-
metry was selected as a critical quality parameter for the
robustness test. The final method provided lumefantrine
peak shape (As 1.3) that complies with pharmacopoeial
specifications. Moreover, even the deliberate method varia-
tions provided better lumefantrine peak shapes (As 1.4 andFigure 3 Contour plots: (a) Acetonitrile (ACN) (% V/V) vs flow (ml/min
(ml/min) for k’ of lumefantrine; (c) temperature (˚C) vs flow (ml/min) f
lumefantrine. For (a), (b) and (d) mobile phase: pH 3, column temperature1.8) (Table 1) than the very tailed lumefantrine peak shape
(As 2.1) reported in the literature [23]. In the stressed sam-
ple solutions, there was no difference in selectivity between
the results of the method setting and the deliberate varia-
tions of both β-artemether and lumefantrine APIs and
their respective degradation products.
Typical contour plots for different chromatographic
parameters as a function of operational variables levels is
presented in Figure 3. Figure 3 (a, b and c) is the visual
representation of sensitivity, i.e. how quantitatively aceto-
nitrile proportion (%ACN), flow rate and temperature in-
fluence the retention factor (k’). Moreover, it is revealed
in the Figure 3 that small deviations from the method
setting introduced in the four parameters do not affect
As and k’-specifications set in Ph. Eur. [27]. The observed
effects for peak symmetry (As) of lumefantrine and k’ for
β-artemether and lumefantrine are presented in Figure 4.
Flow rate and %ACN have more pronounced effect on k’
of both compounds while lumefantrine peak shape was
more affected by %ACN.
The mean content of β-artemether and lumefantrine
was found to be 100.9% lc ± 1.0 (RSD 1.0%) and 99.7%
lc ± 0.4 (RSD 0.4%), respectively (see Additional file 1).
Therefore, the deliberate changes from the method settings
in chromatographic conditions (% V/V of acetonitrile) for retention factor (k’) of β-artemether; (b) ACN (% V/V) vs flow
or k’ of β-artemether; (d) ACN (% V/V) vs flow (ml/min) for As of
: 30°C and for (c) % ACN: 52, mobile phase: pH 3.
Figure 4 Observed effects for peak symmetry (As) of lumefantrine and retention factor (k’) for β-artemether and lumefantrine in the
experimental design space.
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http://www.malariajournal.com/content/12/1/145in mobile phase (from 50 to 54%), flow (from 0.8 to
1.2 ml/min), pH (from 2.8 to 3.2) and column temperature
(from 25 to 35°C)) have little impact on the assay of
β-artemether and lumefantrine containing anti-malarial
FDC products indicating the robustness of the method.Table 4 Contents of β-artemether and lumefantrine in
fixed dose combination (FDC) products (n=6)
FDC samples Batch/Lot
No.
Content (%) ± S.D.
β-artemether Lumefantrine
ArtemineW tablets A 103.2 ± 1.5 101.5 ± 0.9
B 102.2 ± 1.7 101.3 ± 0.5
CoartemW tablets A 98.2 ± 0.9 97.92 ± 0.7
B 99.2 ± 1.5 98.8 ± 0.7
Co-Artesiane powder for oral
suspension
A 100.9 ± 1.9 101.4 ± 0.9
B 99.7 ± 1.6 102.0 ± 0.8
C 101.1 ± 1.3 100.8 ± 0.8
S.D. = standard deviation.Limit of detection (LoD) and limit of quantitation (LoQ)
According to the determined signal-to-noise ratio, the
LoD and LoQ for β-artemether were calculated to be 3.4
μg/ml and 10.0 μg/ml, respectively. For lumefantrine,
LoD was 0.1 μg/ml and its LoQ was 0.4 μg/ml. As the
purpose of this developed method is to quantitatively de-
termine both β-artemether and lumefantrine simultan-
eously in FDC anti-malarial products where the
compounds exist in the mass ratio β-artemether:
lumefantrine of 1:6, the LoD and LoQ values obtained
for β-artemether should be considered as the overall de-
tection and quantification limits, while for lumefantrine,
the risk of overloading the HPLC system is to be con-
sidered. Both opposing aspects are solved with the
proposed method.Analysis of marketed FDC products
The results of real sample analysis are presented in
Table 4. All the analysed batches presented β-artemether
and lumefantrine contents complying with the 95-
105% lc specifications. The β-artemether content in
the tablet samples varied from 98.2% to 103.2% while
lumefantrine content varied from 97.9% to 101.5%. In
Figure 5 In-silico toxicity profile of β-artemether and its impurities.
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http://www.malariajournal.com/content/12/1/145Co-Artesiane powder for oral suspension FDC prod-
uct, β-artemether content was in the range of 99.7%
to 101.1% while that of lumefantrine was ranging from
100.8% to 102.0%.
In-silico toxicological predictions of β-artemether and its
related impurities
In-silico toxicity profile of lumefantrine and its related im-
purities was reported in previous publication [23]. In this
study, mutagenicity, chromosome abrasion, genotoxicity,
skin irritation, hepatotoxicity and nephrotoxicity endpoints
for β-artemether, as well as for its related observed andalready described impurities, have been investigated using
Derek NexusW and the result is presented in Figure 5.
The toxicity profile of β-artemether and all its identified
related degradants and synthetic impurities is defined by
several general toxicity alerts. DHA, α-artemether and
β-artemether were found to have toxicity endpoints for
mutagenicity, chromosomal abrasion, genotoxicity, skin ir-
ritation, hepatogenicity and nephrotoxicity. β-artemether
and all its identified related impurities, except desoxy-
artemisinin which has structural alert for hepatotoxicity,
have substructures for skin irritation. Derek NexusW
did not trigger mutagenicity, chromosomal abrasion
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http://www.malariajournal.com/content/12/1/145and genotoxicity for artemisinin, 9-epi artemisinin,
artemisitene, desoxyartemisinin and AHA.Discussion
The development of rapid, economical and reliable
stability-indicating methods is essential to assure the
quality of anti-malarial drugs in general, and the β-
artemether-lumefantrine FDC anti-malarial products in
particular. The use of poor quality drugs might contrib-
ute to the development of resistance in endemic areas
due to the exposition to subtherapeutic doses [19]. The
quality control of the anti-malarial pharmaceutical prep-
arations currently on the market might help to assure
the efficacy of the treatment and avoid resistance to
these anti-malarial drugs.
A simple, rapid and economical stability-indicating,
fused-core HPLC method has been developed and vali-
dated for the routine quality control tests of β-artemether
and lumefantrine in FDC anti-malarial products. The
method uses a simple sample preparation procedure
(extraction of the APIs with tetrahydrofuran) and is
rapid with a total run time of only four minutes. The
results of stress testing show that the developed assay
method is selective and stability-indicating as it is cap-
able of separating both β-artemether and lumefantrine
from their respective degradation products. Moreover,
the developed method was successfully applied to
quantitatively analyse β-artemether and lumefantrine
in marketed FDC anti-malarial drugs.
Safety of a drug product is dependent not only on the
toxicological properties of the active drug substance, but
also on the toxicological properties of its impurities in-
cluding the possible degradants. Impurity profiling of
both β-artemether and lumefantrine as well as in-silico
toxicity profile of lumefantrine and its related impurities
have been reported in previous publications [20,23,28].
Here, in-silico toxicological profile of β-artemether was
compared against its related identified impurities using
Derek NexusW. Derek NexusW is a computer-based ex-
pert system for the qualitative prediction of possible
toxic action of compounds on the basis of their chem-
ical structure. The system is able to perceive chemical
substructures within molecules and relate these to a
rule-base, linking the substructures with likely types of
toxicity [31]. The toxicity profile of β-artemether and
all its identified related degradants and synthetic im-
purities is defined by several general toxicity alerts for
mutagenicity, chromosomal abrasion, genotoxicity, skin
irritation, hepatotoxicity and nephrotoxicity. However,
no significant difference in in-silico toxicity profile be-
tween β-artemether and its related impurities is ob-
served, which is also consistent with experimentally
obtained Ames mutagenicity results [20].Conclusions
A stability-indicating HPLC method for simultaneous
assay of β-artemether and lumefantrine fixed dose com-
bination anti-malarial products was developed, using a
fused-core reversed-phase amide stationary phase com-
bined with an isocratic acetonitrile sodium phosphate mo-
bile phase [Acetonitrile/1 mM phosphate buffer pH 3.0
(52:48, v/v)]. It is a rapid (four minutes total run time), pre-
cise and accurate method that can be utilized to quantify
these anti-malarials in the presence of their related degrad-
ation products or impurities produced during inadequate
transportation and storage. This method can be applied in
the routine regulatory quality control of β-artemether and
lumefantrine containing FDC drug products. The in-silico
toxicological investigation using Derek NexusW indicated
overall a toxicity risk for β-artemether-related impurities
comparable to that of the API β-artemether itself.
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